GlassScriptPhysician profile
Stephen C Medlin
NPI 1134195159
$50,167.90
in general payments reported to CMS, 2019-2025
14 companies · $24K in 2025
The $24K reported for 2025 was more than what 86% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $1,719 · 2021: $4,931 · 2022: $16K · 2023: $2,520 · 2024: $549 · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $1,597 · Travel and Lodging: $305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,190.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,790.00 |
| Food and Beverage | $1,596.99 |
| Travel and Lodging | $304.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $34,856.42 | 2019-2025 | Yescarta |
| Astrazeneca Pharmaceuticals LP | $8,540.01 | 2019-2022 | |
| Morphosys, US INC. | $1,845.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $1,730.00 | 2023 | |
| Seagen INC. | $1,375.00 | 2022 | |
| Adaptive Biotechnologies Corporation | $1,270.98 | 2021 | |
| Legend Biotech USA INC. | $215.34 | 2024 | |
| Janssen Scientific Affairs, LLC | $135.10 | 2025 | Carvykti |
| Tempus Ai, INC | $115.44 | 2024 | |
| Siemens Medical Solutions USA, INC. | $38.38 | 2024 | |
| Janssen Global Services, LLC | $27.56 | 2025 | |
| Amgen INC. | $18.67 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Medlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.